Sensei Biotherapeutics, INC 10-Q quarterly reports

Faeth Therapeutics announced its Q2 2026 financial results, detailing a significant increase in operating expenses and net loss following the acquisition of Faeth Therapeutics and a concurrent private placement.

Sensei Biotherapeutics announces significant increase in operating expenses and net loss for Q1 2026, primarily due to the acquisition of Faeth Therapeutics and associated costs.

Sensei Biotherapeutics discontinues its lead therapeutic candidate, solnerstotug, implements a 65% workforce reduction, and explores strategic alternatives including a potential wind-down, raising substantial doubt about its ability to continue as a going concern.

Sensei Biotherapeutics reported reduced operating losses and extended its cash runway into Q2 2026 by pausing preclinical programs and focusing on its lead cancer therapeutic, solnerstotug, despite ongoing going concern doubts.

Sensei Biotherapeutics announces its Q1 2025 financial results, highlighting a net loss of $6.9 million and expressing substantial doubt about its ability to continue as a going concern without additional financing.

Sensei Biotherapeutics reports Q3 2024 results, announces a strategic realignment to focus on SNS-101, and extends its cash runway into Q2 2026.

Sensei Biotherapeutics reports a net loss of $15.1 million for the first half of 2024, while providing an update on its clinical trial for SNS-101 and extending its cash runway into the fourth quarter of 2025.

Sensei Biotherapeutics reports a net loss of $7.992 million for the first quarter of 2024, while advancing its clinical programs and managing operating expenses.